RTTNews | Dec 28, 2021 08:13AM EST

08:12 Tuesday, December 28, 2021 (RTTNews.com) - Palatin Technologies Inc. (PTN) said on Tuesday that it has initiated a pivotal phase III clinical study of PL9643, an ophthalmic solution, in patients with dry eye disease.

The trial, dubbed MELODY-1, is designed to enroll up to 400 patients in multiple U.S. sites, and top-line results are currently anticipated in the second half of 2022.

Carl Spana, CEO of Palatin, commented: "This is the second melanocortin peptide Palatin has advanced into Phase 3, demonstrating Palatin's expertise and efficiency in melanocortin peptide development for indications with unmet medical need."

Read the original article on RTTNews ( https://www.rttnews.com/3251725/palatin-advances-pl9643-for-the-treatment-of-dry-eye-disease-into-phase-3-study.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved